Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based biotechnology company United Therapeutics and its wholly-owned subsidiary Lung Rx, have announced that the FDA has accepted for review the new drug application for inhaled treprostinil.
Subscribe to our email newsletter
The new drug application (NDA) will be subject to a standard review period of 10 months, with a targeted user fee deadline of April 30, 2009.
According to the company, inhaled treprostinil is developed for the treatment of pulmonary arterial hypertension.